Literature DB >> 21754960

Metformin-induced cholangiohepatitis.

Raja Shekhar Reddy Sappati Biyyani1, Smitha Battula, Christopher A Erhardt, Khalil Korkor.   

Abstract

Drug-induced cholangiohepatitis accounts for 20-50% of non-viral chronic hepatitis cases. Metformin is the most commonly prescribed oral anti-diabetic drug from the biguanide class used in treatment of overweight and obese type 2 diabetes mellitus patients. Metformin-induced cholangiohepatitis with marked elevations in serum liver transaminases and intrahepatic cholestasis has been infrequently reported. Here, we report a case of acute cholangiohepatitis after initiation of metformin treatment.

Entities:  

Year:  2009        PMID： 21754960      PMCID： PMC3028181          DOI： 10.1136/bcr.09.2008.0950

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  9 in total

Review 1.  Drug-induced cholestasis.

Authors:  S Chitturi; G C Farrell
Journal:  Semin Gastrointest Dis       Date:  2001-04

2.  Metformin-induced acute hepatitis.

Authors:  M M Babich; I Pike; M L Shiffman
Journal:  Am J Med       Date:  1998-05       Impact factor: 4.965

3.  Cholestatic jaundice associated with the use of metformin.

Authors:  D J Desilets; A F Shorr; K A Moran; K C Holtzmuller
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

4.  Possible metformin-induced hepatotoxicity.

Authors:  Eiji Kutoh
Journal:  Am J Geriatr Pharmacother       Date:  2005-12

Review 5.  Metformin.

Authors:  C J Bailey; R C Turner
Journal:  N Engl J Med       Date:  1996-02-29       Impact factor: 91.245

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 7.  Drug-induced cholestasis.

Authors:  D Larrey; S Erlinger
Journal:  Baillieres Clin Gastroenterol       Date:  1988-04

8.  Metformin-induced cholestatic hepatitis.

Authors:  Fadel E Nammour; Nabil F Fayad; Steven R Peikin
Journal:  Endocr Pract       Date:  2003 Jul-Aug       Impact factor: 3.443

Review 9.  Metformin: an update.

Authors:  Dmitri Kirpichnikov; Samy I McFarlane; James R Sowers
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391
  9 in total
  2 in total

1.  Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk.

Authors:  Fleur Lien; Alexandre Berthier; Emmanuel Bouchaert; Céline Gheeraert; Jeremy Alexandre; Geoffrey Porez; Janne Prawitt; Hélène Dehondt; Maheul Ploton; Sophie Colin; Anthony Lucas; Alexandre Patrice; François Pattou; Hélène Diemer; Alain Van Dorsselaer; Christophe Rachez; Jelena Kamilic; Albert K Groen; Bart Staels; Philippe Lefebvre
Journal:  J Clin Invest       Date:  2014-02-17       Impact factor: 14.808

2.  Literature review of the clinical characteristics of metformin-induced hepatotoxicity.

Authors:  Chunjiang Wang; Hongyi Deng; Yunfei Xu; Ying Liu
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.